IRIS
FAVOINO, ELVIRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.596
EU - Europa 2.359
AS - Asia 1.943
SA - Sud America 513
Continente sconosciuto - Info sul continente non disponibili 265
AF - Africa 89
OC - Oceania 1
Totale 9.766
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.509
RU - Federazione Russa 830
SG - Singapore 757
IT - Italia 713
CN - Cina 453
BR - Brasile 407
HK - Hong Kong 252
SE - Svezia 218
VN - Vietnam 154
DE - Germania 127
FR - Francia 119
FI - Finlandia 91
GB - Regno Unito 82
UA - Ucraina 79
IN - India 61
BD - Bangladesh 59
AR - Argentina 38
ID - Indonesia 38
CA - Canada 34
TR - Turchia 31
MX - Messico 23
PL - Polonia 20
ZA - Sudafrica 20
CI - Costa d'Avorio 18
CO - Colombia 18
JP - Giappone 17
NL - Olanda 17
IQ - Iraq 16
AT - Austria 14
BE - Belgio 14
MY - Malesia 13
PK - Pakistan 13
UZ - Uzbekistan 13
EC - Ecuador 12
CL - Cile 11
TN - Tunisia 10
ES - Italia 9
PH - Filippine 9
DZ - Algeria 8
SA - Arabia Saudita 8
VE - Venezuela 8
PY - Paraguay 7
CR - Costa Rica 6
EG - Egitto 6
IE - Irlanda 6
MA - Marocco 6
AE - Emirati Arabi Uniti 5
AZ - Azerbaigian 5
JO - Giordania 5
PE - Perù 5
TH - Thailandia 5
UY - Uruguay 5
DO - Repubblica Dominicana 4
JM - Giamaica 4
KE - Kenya 4
LT - Lituania 4
PA - Panama 4
SY - Repubblica araba siriana 4
TT - Trinidad e Tobago 4
GE - Georgia 3
HR - Croazia 3
IL - Israele 3
LB - Libano 3
NP - Nepal 3
XK - ???statistics.table.value.countryCode.XK??? 3
AL - Albania 2
AO - Angola 2
BB - Barbados 2
BO - Bolivia 2
BW - Botswana 2
CG - Congo 2
EE - Estonia 2
KR - Corea 2
MM - Myanmar 2
PR - Porto Rico 2
PS - Palestinian Territory 2
SV - El Salvador 2
ZW - Zimbabwe 2
AM - Armenia 1
AU - Australia 1
BF - Burkina Faso 1
BH - Bahrain 1
BZ - Belize 1
CH - Svizzera 1
ET - Etiopia 1
EU - Europa 1
GA - Gabon 1
GH - Ghana 1
GR - Grecia 1
HU - Ungheria 1
IM - Isola di Man 1
IR - Iran 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MK - Macedonia 1
ML - Mali 1
NG - Nigeria 1
NI - Nicaragua 1
PT - Portogallo 1
Totale 9.498
Salva come PNG Salva come JPEG
Città #
Ashburn 449
Fairfield 421
Singapore 383
Chandler 311
Woodbridge 263
Houston 255
Hong Kong 251
San Jose 250
Milan 215
Bari 211
Jacksonville 209
Ann Arbor 189
Nyköping 186
Cambridge 184
Seattle 180
Wilmington 168
Beijing 140
Council Bluffs 104
Rome 91
Nanjing 72
Lauterbourg 69
New York 66
Roxbury 63
Lawrence 60
Boardman 59
Los Angeles 52
Dallas 48
Des Moines 42
Ho Chi Minh City 42
Princeton 36
Helsinki 34
Inglewood 34
Columbus 30
Hanoi 30
Santa Clara 30
Moscow 27
São Paulo 24
Buffalo 23
Dearborn 23
Jakarta 21
London 21
Pune 20
Brooklyn 19
Falkenstein 19
Shenyang 19
Abidjan 18
Orem 18
Warsaw 18
San Diego 17
Tokyo 17
Turin 17
Frankfurt am Main 16
Munich 16
Paris 16
Phoenix 16
Chicago 15
Belo Horizonte 14
Dong Ket 14
Montreal 14
Rio de Janeiro 14
Brussels 13
Haiphong 13
Noicattaro 13
Tashkent 13
Atlanta 11
Chennai 11
Figino 11
Guangzhou 11
Nanchang 11
Amsterdam 10
Nuremberg 10
San Francisco 10
Tianjin 10
Boston 9
Hebei 9
The Dalles 9
Ankara 8
Johannesburg 8
Mexico City 8
Vienna 8
Changsha 7
Denver 7
Poplar 7
Shanghai 7
Stockholm 7
Campinas 6
Dublin 6
Fortaleza 6
Indiana 6
Jiaxing 6
Kuala Lumpur 6
Medellín 6
Naples 6
Porto Alegre 6
Toronto 6
Washington 6
Auburn Hills 5
Bologna 5
Brasília 5
Buenos Aires 5
Totale 6.010
Salva come PNG Salva come JPEG
Nome #
Response to "Is active acid sphingomyelinase required for the antiproliferative response to rituximab?" [e-letter]. http://bloodjournal.hematologylibrary.org/content/117/13/3695.citation/reply#bloodjournal_el_2268 769
Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: An intriguing association 226
ANTIBODIES TO ENDOPLASMIN AND THEIR USE 205
CD20-Mimotope Peptides: A Model to Define the Molecular Basis of Epitope Spreading 200
Methods for treating a tumor using an antibody that specifically binds HMW-MAA 198
Clinical correlates of human leucocyte antigen (HLA)-G in systemic sclerosis 188
Autoantibodies Recognizing the Amino Terminal 1-17 Segment of CENP-A Display Unique Specificities in Systemic Sclerosis 182
Anti-centromere protein A antibodies in systemic sclerosis: Significance and origin 181
CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases 172
Evaluation of the influence of social, demographic, environmental, work-related factors and/or lifestyle habits on Raynaud's phenomenon: a case-control study 171
Oxidized low density lipoproteins: The bridge between atherosclerosis and autoimmunity. Possible implications in accelerated atherosclerosis and for immune intervention in autoimmune rheumatic disorders. 166
AB0695 Subspecificities of Anti-Centromeric-Associated Protein a (CENP-A) Antibodies (AB) Can Identified a Subset of Patients at Higher Risk of Developing Pulmonary Hypertension 159
Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease 157
Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis 151
CD20 mimicry by a mAb rituximab-specific linear peptide: A potential tool for active immunotherapy of autoimmune diseases 151
Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart? 147
Rheumatic disorders as paraneoplastic syndromes 143
CD20: A target antigen for immunotherapy of autoimmune diseases 139
Effects of Adjuvants for Human Use in Systemic Lupus Erythematosus (Sle)-Prone (Nzb/Nzw) F1 Mice 138
Abstract 4390: Heat shock protein (HSP) Grp94-targeted combinatorial immunotherapy for pancreatic cancer 137
Anti-carbamylated protein antibodies in patients with systemic sclerosis: an intriguing association with skin involvement 132
The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells 130
Biological therapy with monoclonal antibodies: a novel treatment approach to autoimmune disease 130
CD20 mimicry by mAb Rituximab-specific linear peptide. A potential tool for active immunotherapy of autoimmune diseases 128
Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor 127
Identification of an antigenic and immunogenic motif expressed by two 7-Mer Rituximab-specific cyclic peptides 127
Dietary cholesterol supplementation and inhibitory factor 1 serum levels in two dizygotic Smith-Lemli-Opitz syndrome twins: a case report 127
Circulating Irisin Levels in Patients with Chronic Plaque Psoriasis. 123
Beta2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide 122
Antitumor activity of BRAF inhibitor and IFN×alpha; Combination in BRAF-mutant melanoma 121
SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial? 121
Sars-cov-2 inflammatory syndrome. Clinical features and rationale for immunological treatment 121
Novel combinatorial therapy for pancreatic adenocarcinoma 120
Two structurally different rituximab-specific CD20 mimotope peptides reveal that rituximab recognizes two different CD20-associated epitopes 118
Endothelial cells in tumor microenvironment: insights and perspectives 117
Low mortality rate in Italian rheumatoid arthritis patients from a tertiary center: Putative implication of a low anti-carbamylated protein antibodies prevalence 114
HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors 113
CSPG4 in cancer: Multiple roles 112
Identification of an antigenic and immunogenic motif expressed by two 7-mer rituximab-specific cyclic peptide mimotopes: Implication for peptide-based active immunotherapy 111
Identificazione del peptide che mima l'epitopo localizzato sulla catena pesante HLA-I non associata alla beta 2-microglobulina, riconosciuto dall'anticorpo monoclonale HC-10 106
HLA allele prevalence in disease-modifying antirheumatic drugs-responsive enthesitis and/or arthritis not fulfilling ASAS criteria: Comparison with psoriatic and undifferentiated spondyloarthritis 105
Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count 104
Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy, Cancer Initiating Cells and Disease Recurrence 104
Characterization of the specificity of the Human scFv W9 104
Circulating Inhibitory Factor 1 levels in adult patients with Prader-Willi syndrome 103
Targeting cancer initiating cells in pancreatic adenocarcinoma 97
Harnessing host innate immunity may combat acquired resistance to BRAFi 96
Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4 96
Raynaud’s phenomenon: from molecular pathogenesis to therapy 95
EXPRESSION OF THE TRANSCRIPTION FACTOR FORKHEAD BOX E3 (FOXE3) IN MONOCYTES FROM PATIENTS WITH SYSTEMIC SCLEROSIS AND CORRELATION WITH THEIR SEROLOGICAL PROFILE 93
EXPRESSION OF THE TRANSCRIPTION FACTOR FORKHEAD BOX E3 (FOXE3) IN PERIPHERAL BLOOD MONONUCLEAR CELLS OF PATIENTS WITH SYSTEMIC SCLEROSIS 91
AUTO-ANTIBODIES TO THE AMINO TERMINAL SEGMENT (AMINOACID 1-17) OF CENP-A DISPLAY A UNIQUE SPECIFICITY IN SYSTEMIC SCLEROSIS AND ARE INDEPENDENTLY EXPRESSED FROM THOSE AGAINST CENP-B 91
Insight into the specificità of the anti-CD20 monclonal antibody Rituximab. 89
Ruolo degli autoanticorpi nelle patologie autoimmuni 88
Human CD4 mimicry by anti-idiotypic monoclonal antibody 16D7 is based on a conformational epitope 88
Metodo ELISA: dosaggio della catena pesante della molecola HLA non associata alla b2-microglobulina 86
Phlegmonous abscess associated with etanercept therapy 83
Ruolo degli autoanticorpi nelle patologie autoimmuni 82
Idiopathic and connective tissue disease-associated pulmonary arterial hypertension (PAH): Similarities, differences and the role of autoimmunity 81
Chronic-Relapsing cutaneous leukocytoclastic vasculitis in a young patient with reduced EBV-specific T cell response using enzyme-linked immunospot (ELISPOT) assay successfully treated with Valaciclovir 79
Systemic sclerosis and primary biliary cholangitis share an antibody population with identical specificity 78
Peptidi che mimano l'antigene CD20: potenzialità terapeutiche nel lupus eritematoso sistemico 77
Poems syndrome with amyloidosis and calchyphylaxis.A case report 77
null 77
Two structurally different peptides mimic a CD20 epitope recognized by rituximab 74
Identification of an antigenic and immunogenic motif expressed by two 7-Mer Rituximab-specific cyclic peptides. Journal of Immunology 74
Functional characterization of peptides mimicking the CD20 epitope recognized by Rituximab 73
Quantitative evaluation of anti-FOXE-3 Ab identifies a subset of anti-CENP positive systemic sclerosis patients who are less prone to develop active disease 70
Why Do We Still Lack a COVID-19 Vaccine? Searching for the Missing Pieces 70
Generation of linear and cyclic peptides revealed a unique fine specificity of Rituximab and its possible cross-reactivity with an acid sphingomyelinase-like phosphodiesterasem 3B precursor 69
 Peptides highly specific to the variable region of TNF-ALFA-specific references licensed (RL) monoclonal antibodies (MAB), as potential tool to effectively assess similarity between biosimilars and the correspondig RL MAB 69
Impact of belimumab therapy on the quality of life in patients with systemic lupus erythematosus: A cohort study 68
Novel biomarker for pulmonary vascular disease in systemic sclerosis patients 64
Mimotope peptides in the immunization against CD20: a promising approach to the therapy of autoimmune diseases 59
Clinical and subclinical atherosclerosis in patients with systemic sclerosis: an observational, multicentre study of GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) 50
Primary versus systemic-sclerosis-associated Raynaud's phenomenon: relationship with clinical and environmental factors 50
Classic pyoderma gangrenosum 50
null 49
Methods for treating a tumor using an antibody that specifically binds grp94 47
Clinical correlates of a subset of anti-fibroblast antibodies in systemic sclerosis 38
β2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide 35
Barriers to therapy adherence in a group of Italian patients with systemic lupus erythematosus 34
null 33
Type II diabetes in systemic sclerosis patients: insights from an observational, multicenter study of GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) 32
Functional characterization of peptides mimicking the CD-20 epitope recognized by Rituximab 32
Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAFV600E melanoma 24
Clinical associations and related factors of metabolic syndrome in systemic sclerosis: results from an observational multicenter study of GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) 12
Novel Biomarker for Antimitochondrial Antibodies in Systemic Sclerosis Patients 10
Inflammatory biomarkers of atherosclerosis in SLE that may improve SLE-specific cardiovascular risk assessment tools 7
Takayasu Arteritis and Giant Cell Arteritis: Results From a Cross‐Sectional Study of 96 Italian Patients 5
Effectiveness and safety of Janus Kinase inhibitors in patients with rheumatoid arthritis, results from a multicenter observational “real‑life” GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study 4
Totale 9.766
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.086
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.086
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022431 0 0 6 18 22 34 51 22 32 23 97 126
2022/2023844 122 94 45 74 107 105 29 116 113 9 16 14
2023/2024363 24 53 19 70 21 77 11 21 8 8 6 45
2024/20251.280 79 18 114 20 28 86 158 106 53 67 178 373
2025/20263.707 396 159 181 374 307 170 354 93 934 255 82 402
2026/2027369 106 150 113 0 0 0 0 0 0 0 0 0
Totale 9.766